Beta Bionics

Executive Summary

Beta Bionics is a medical device company pioneering automated insulin delivery with its iLet Bionic Pancreas, a closed-loop system that uses continuous glucose monitor data to autonomously adjust insulin dosing. The company has received FDA de novo clearance and launched the iLet for Type 1 diabetes, reducing the burden of daily diabetes management. With a strong focus on user experience and clinical outcomes, Beta Bionics aims to expand its platform to broader patient populations. The company is privately held and headquartered in Concord, Massachusetts, with potential for significant market capture given the large diabetes population and increasing adoption of automated insulin delivery systems. However, competition from Medtronic, Tandem, and Insulet remains intense, and sustained commercial execution is critical.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval for Type 2 Diabetes Indication70% success
• Q2 2027Launch of Next-Generation iLet with Integrated CGM60% success
• H1 2027Reimbursement Expansion via Medicare and Commercial Payers80% success